North America Spearheading the Global Kidney Cancer Drugs Market
- Submitted by: Alinajohn
- Views: 84
- Category: English: Creative Writing
- Date Submitted: 07/06/2015 11:35 PM
- Pages: 4
- Report this Essay
Kidney cancer is considered to be one of the 10 most common cancers affecting men and women across the globe. While the risk of kidney cancer is higher in men than in women, there are numerous factors that determine the risk of cancer. The two main types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney cancer drugs are generally administered to patients of stage four, advanced RCC.
Browse Full Global Kidney Cancer Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.
The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.
Votrient: Most promising commercially available kidney cancer drug
There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).
Of these, Sutent (Sunitinib) dominated the kidney cancer drugs market in 2013, accounting for 30% of the revenue share. Often considered to be the first line of treatment for renal cell carcinoma (RCC), Sutent is one of the most studied kidney cancer drugs for multiple indications. However, owing to its relatively high price, this drug is expected to register a rather meager growth rate of 1.1% from 2012 to 2016 and 2.1% from 2016 to 2020....
Browse Full Global Kidney Cancer Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.
The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.
Votrient: Most promising commercially available kidney cancer drug
There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).
Of these, Sutent (Sunitinib) dominated the kidney cancer drugs market in 2013, accounting for 30% of the revenue share. Often considered to be the first line of treatment for renal cell carcinoma (RCC), Sutent is one of the most studied kidney cancer drugs for multiple indications. However, owing to its relatively high price, this drug is expected to register a rather meager growth rate of 1.1% from 2012 to 2016 and 2.1% from 2016 to 2020....